Bharat Biotech, which has been accorded Emergency Use Authorisation from the drug regulator for its COVID-19 vaccine Covaxin, on Monday said they are setting up four vaccine manufacturing facilities with a combined capacity of 700 million doses per annum.
Denying allegations that the city-based vaccine maker lacks data of Covaxin, Krishna Ella, chairman of Bharat Biotech, said sufficient data has already been revealed and is available on the net.
"We have four facilities coming up. We are planning around 200 million doses (per annum) in Hyderabad, 500 million doses in other cities.
By 2021 we will have 7,600 million doses capacity... as we speak we have 20 million doses, he told reporters.
He said Covaxin is currently undergoing phase 3 clinical trials with 24,000 volunteers.
"I think we are the only company I can categorically say has got extensive research experience and extensive publication peer reviewed journals.
Many people say that I am not transparent in my data.
I think people should have the patience to read internet and look at what our articles are," he said on the allegations of data availability.
He said Indian companies are being targeted as inferior ones and said his companys work is no less than Pfizer, which also came out with a vaccine for coronavirus.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU